139 related articles for article (PubMed ID: 9440486)
1. Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator.
Ohara M; Tsutsumi K; Ohsawa N
Metabolism; 1998 Jan; 47(1):101-5. PubMed ID: 9440486
[TBL] [Abstract][Full Text] [Related]
2. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Goto T
Anticancer Res; 1999; 19(5B):4099-103. PubMed ID: 10628360
[TBL] [Abstract][Full Text] [Related]
3. Lipid metabolism in cachectic tumor-bearing rats at different stages of tumor growth.
Obeid OA; Emery PW
Nutr Cancer; 1993; 19(1):87-98. PubMed ID: 8446517
[TBL] [Abstract][Full Text] [Related]
4. NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.
Kusunoki M; Tsutsumi K; Iwata K; Yin W; Nakamura T; Ogawa H; Nomura T; Mizutani K; Futenma A; Utsumi K; Miyata T
Metabolism; 2005 Dec; 54(12):1587-92. PubMed ID: 16311090
[TBL] [Abstract][Full Text] [Related]
5. The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells.
Hagi A; Hirai I; Kohri H; Tsutsumi K
Biol Pharm Bull; 1997 Oct; 20(10):1108-10. PubMed ID: 9353574
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein lipase and atherosclerosis.
Tsutsumi K
Curr Vasc Pharmacol; 2003 Mar; 1(1):11-7. PubMed ID: 15320848
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate.
Nomura K; Noguchi Y; Matsumoto A
Surg Today; 1996; 26(2):89-94. PubMed ID: 8919277
[TBL] [Abstract][Full Text] [Related]
8. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Naoe Y; Inami M; Manda T; Shimomura K
Anticancer Res; 1999; 19(1A):341-8. PubMed ID: 10226565
[TBL] [Abstract][Full Text] [Related]
9. Relationship of organ lipoprotein lipase activity and ketonuria to hypertriglyceridemia in starved and streptozocin-induced diabetic rats.
Wilson DE; Zeikus R; Chan IF
Diabetes; 1987 Apr; 36(4):485-90. PubMed ID: 3817303
[TBL] [Abstract][Full Text] [Related]
10. Effect of acute acipimox administration on the rates of lipid and glycogen synthesis in cachectic tumor-bearing rats.
Obeid OA; Emery PW
Nutr Cancer; 1997; 28(1):100-6. PubMed ID: 9200157
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein lipase activity in adipose tissue and skeletal muscle of runners: relation to serum lipoproteins.
Nikkilä EA; Taskinen MR; Rehunen S; Härkönen M
Metabolism; 1978 Nov; 27(11):1661-7. PubMed ID: 212665
[TBL] [Abstract][Full Text] [Related]
12. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats.
Tsutsumi K; Inoue Y; Shima A; Murase T
Diabetes; 1995 Apr; 44(4):414-7. PubMed ID: 7698509
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model.
Carbó N; Costelli P; Tessitore L; Bagby GJ; López-Soriano FJ; Baccino FM; Argilés JM
Clin Sci (Lond); 1994 Sep; 87(3):349-55. PubMed ID: 7955912
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.
Kusunoki M; Tsutsumi K; Sato D; Nakamura A; Habu S; Mori Y; Morishita M; Yonemoto T; Miyata T; Nakaya Y; Nakamura T
Eur J Pharmacol; 2011 Oct; 668(3):486-91. PubMed ID: 21835171
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein lipase activator NO-1886.
Yin W; Tsutsumi K
Cardiovasc Drug Rev; 2003; 21(2):133-42. PubMed ID: 12847564
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein lipase in white and brown adipose tissues of exercised rats fed a high-fat diet.
Deshaies Y; Arnold J; Lalonde J; Richard D
Am J Physiol; 1988 Aug; 255(2 Pt 2):R226-31. PubMed ID: 3407799
[TBL] [Abstract][Full Text] [Related]
17. Effect of diet on adipose tissue and skeletal muscle VLDL receptor and LPL: implications for obesity and hyperlipidemia.
Roberts CK; Barnard RJ; Liang KH; Vaziri ND
Atherosclerosis; 2002 Mar; 161(1):133-41. PubMed ID: 11882325
[TBL] [Abstract][Full Text] [Related]
18. The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity.
Tsutsumi K; Inoue Y; Hagi A; Murase T
Metabolism; 1997 Mar; 46(3):257-60. PubMed ID: 9054466
[TBL] [Abstract][Full Text] [Related]
19. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet.
Kusunoki M; Hara T; Tsutsumi K; Nakamura T; Miyata T; Sakakibara F; Sakamoto S; Ogawa H; Nakaya Y; Storlien LH
Diabetologia; 2000 Jul; 43(7):875-80. PubMed ID: 10952460
[TBL] [Abstract][Full Text] [Related]
20. Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model.
Briddon S; Beck SA; Tisdale MJ
Cancer Lett; 1991 Apr; 57(1):49-53. PubMed ID: 2025878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
